Agenus presents data at asco gi demonstrating impact of bot/bal in colorectal cancer across neoadjuvant and advanced disease

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today shared new data on botensilimab (bot) and balstilimab (bal) at the american society of clinical oncology gastrointestinal cancers symposium (asco gi) in san francisco. data from five presentations underscore the transformative potential of bot/bal across multiple lines of therapy in colorectal cancer, including neoadjuvant, first-line, and refractory settings. data presented also highlight bot/bal'.
AGEN Ratings Summary
AGEN Quant Ranking